Wu Haitao

Wu Haitao

Chief Physician, MD, PhD, Doctoral Supervisor, Dr.. Vice President of the Department of Otolaryngology, Eye, Ear, Nose and Throat Hospital Affiliated to Fudan University, and Deputy Director of the Department of Otolaryngology

OncologyENT
Eye, Ear, Nose and Throat Hospital Affiliated to Fudan University (Shanghai ENT Hospital) logo Affiliated HospitalEye, Ear, Nose and Throat Hospital Affiliated to Fudan University (Shanghai ENT Hospital)

Recipient of the Ministry of Education's New Century Excellent Talents Award, the National Science Fund for Distinguished Young Scholars, and the Shanghai Science and Technology Commission's Outstanding Academic Leader Award. Member of the Shanghai Branch of the Chinese Medical Association's Otolaryngology Branch, Head of the Head and Neck Surgery Group; Member of the Head and Neck Tumor Surgery Committee of the Chinese Anti-Cancer Association; Vice Chairman of the Head and Neck Tumor Committee of the Shanghai Anti-Cancer Association. Graduated from Shanghai Medical University in 1997 with a PhD in Clinical Medicine. Specialties include surgical treatment of laryngeal diseases (such as vocal cord polyps, vocal cord leukoplakia, vocal cord adhesions, and vocal cord paralysis); function-preserving surgery for laryngeal cancer and voice reconstruction after total laryngectomy; surgical treatment of tonsil cancer and laryngopharyngeal cancer; and free flap repair of defects after head and neck tumor surgery. Proficient in minimally invasive treatment and function preservation of precancerous lesions of the laryngeal cavity (vocal cord leukoplakia), laryngeal cancer, and hypopharyngeal cancer. He possesses exceptional skills in free flap repair after head and neck tumor surgery, providing patients with high-quality solutions that combine functional preservation and aesthetic reconstruction. He has long been engaged in research on the molecular mechanisms of allergies and nasal inflammation, and in the past five years has led his team to publish over 50 SCI papers with a total impact factor exceeding 150.